CLINICAL_TRIALS
trial_result
· 2021-01-12
Clinical Trial Update: Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial [Phase 3]
Summary
A multicenter Phase 3 open-label trial evaluated ambrisentan in portopulmonary hypertension; results have been posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tufts Medical Center | Conditions: Portopulmonary Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2021-01-12